ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 47.2% in January

ProQR Therapeutics N.V. (NASDAQ:PRQR) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 1,785,809 shares, an increase of 47.2% from the January 15th total of 1,213,326 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average daily volume of 439,616 shares, the days-to-cover ratio is currently 4.1 days. Based on an average daily volume of 439,616 shares, the days-to-cover ratio is currently 4.1 days. Currently, 1.9% of the shares of the company are sold short.

ProQR Therapeutics Trading Up 5.0%

Shares of NASDAQ:PRQR opened at $1.46 on Friday. The firm’s 50 day moving average is $1.87 and its two-hundred day moving average is $2.13. The firm has a market capitalization of $153.61 million, a P/E ratio of -3.11 and a beta of 0.20. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $3.10.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Walleye Capital LLC grew its holdings in ProQR Therapeutics by 11.2% during the fourth quarter. Walleye Capital LLC now owns 591,785 shares of the biopharmaceutical company’s stock worth $1,195,000 after acquiring an additional 59,808 shares during the period. Jane Street Group LLC grew its stake in shares of ProQR Therapeutics by 1,388.5% in the 4th quarter. Jane Street Group LLC now owns 160,175 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 149,414 shares during the last quarter. Simplex Trading LLC raised its holdings in shares of ProQR Therapeutics by 44,169.0% in the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 44,169 shares in the last quarter. Geode Capital Management LLC lifted its stake in ProQR Therapeutics by 73.9% during the fourth quarter. Geode Capital Management LLC now owns 84,909 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 36,087 shares during the last quarter. Finally, Privium Fund Management B.V. lifted its stake in ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after purchasing an additional 359,475 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ProQR Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $7.14.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.